Wei Han

Wei Han


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
CXChuanying Xu
Chuanying Xu
SZShunying Zhu
Shunying Zhu
MWMingyuan Wu
Mingyuan Wu
WHWei Han
Wei Han
YYYan Yu
Yan Yu
Midkine (MK) and pleiotrophin (PTN) belong to the subfamily of heparin binding growth factors. They have ca. 50% structural homology, with similar C- and N-domains as well as comparable binding affinity to heparin, glycoproteins and proteoglycans. Both MK and PTN have diverse functions, such as mitogenicity, inflammation, angiogenesis, oncogenesis and stem cell self-renewal. The high expression of MK and PTN in many kinds of cancers makes them excellent as cancer biomarkers and targets for anticancer drug development. In addition, the important roles of MK and PTN in the regeneration of tissues, such as myocardium, cartilage, neuron, muscle, and bone, make them attractive candidates for the treatment of degenerative diseases such as myocardiac and cerebral infarction, Alzheimer’s disease, Parkinson’s disease and skeletal muscle injury. As a result, there has been a growing interest in the mechanisms of MK and PTN function, including the diverse receptors on the cell membrane and complex signal pathways in the cytoplasm. This work reviews the structures of MK and PTN, as well as the receptors and the intracellular signal pathways involving MK and PTN which will pave the way for future development of MK and PTN therapeutics.

1 February 2019 in Cancer Letters
Verified
Journal Article
Closed access
SDShaorong Deng
Shaorong Deng
QDQing Deng
Qing Deng
YZYingjie Zhang
Yingjie Zhang
HYHao Ye
Hao Ye
XYXiaolan Yu
Xiaolan Yu
WHWei Han
Wei Han

1 February 2006 in Cell Research
Verified
Journal Article
Open access
PDF file
WHWei Han
Wei Han
YYYan Yu
Yan Yu
XLXin Yuan Liu
Xin Yuan Liu
The cellular basis of bone marrow (BM) tissue development and regeneration is mediated through hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs). Local interplays between hematopoietic cells and BM stromal cells (BMSCs) determine the reconstitution of hematopoiesis after myelosuppression. Here we review the BM local signals in control of BM regeneration after insults. Hematopoietic growth factors (HGFs) and cytokines produced by BMSCs are primary factors in regulation of BM hematopoiesis. Morphogens which are critical to early embryo development in multiple species have been added to the family of HSCs regulators, including families of Wnt proteins, Notch ligands, BMPs, and Hedgehogs. Global gene expression analysis of HSCs and BMSCs has begun to reveal signature groups of genes for both cell types. More importantly, analysis of global gene expression coupled with biochemical and biological studies of local signals during BM regeneration have strongly suggested that HGFs and cytokines may not be the primary local regulators for BM recovery, rather chemokines (SDF-1, FGF-4) and angiogenic growth factors (VEGF-A, Ang-1) play instructive roles in BM reconstitution after myelosuppression. A new direction of management of BM toxicity is emerging from the identification of BM regenerative regulators.

6 May 2014 in Cancer Biology & Therapy
Verified
Journal Article
Closed access
JGJing Gao
Jing Gao
LQLan Qian
Lan Qian
XWXia Wang
Xia Wang
MWMingyuan Wu
Mingyuan Wu
YZYang Zhang
Yang Zhang
WHWei Han
Wei Han
Chemotherapy-induced mucositis (CIM) is a major does limiting side-effect of chemoagents such as 5-fluorouracil (5-FU). Molecules involved in this disease process are still not fully understood. We...

1 July 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
PLPing Luo
Ping Luo
SDShaorong Deng
Shaorong Deng
HYHao Ye
Hao Ye
XYXiaolan Yu
Xiaolan Yu
QDQing Deng
Qing Deng
WHWei Han
Wei Han
Interleukin (IL)-33 is a member of the IL-1 family, participating in both helper T1 (Th1)- and Th2-type immune responses, but its ambiguous effects on tumor growth and related immune mechanisms remain unclear. Here, we report that recombinant mouse IL-33 (mIL-33) significantly inhibited colon cancer growth and metastasis to lung and liver in a murine CT26 or MC38 tumor-cell engraftment model. This effect could be associated with CD4+ T cells and CD40 L signaling, as depletion of CD4+ T cells or blocking CD40 L signaling in vivo partly abolished the antitumor function of IL-33. In addition, IL-33 treatment upregulated CD40 L expression on tumor-infiltrating lymphocytes, and promoted the activation of CD4+ T, CD8+ T and natural killer cells via CD40 L signaling. Furthermore, IL-33 was sufficient to induce the ST2 expression on CD4+ T cells, but not on CD8+ T and natural killer cells, indicating that IL-33 acted on CD4+ T cells via a positive-feedback loop. Our findings shed new light on the IL-33-mediated antitumor effects and mechanisms of Th1 action, and also suggest that IL-33 may serve as an activator to boost anticancer immune responses in singular or combinatory therapies.

1 August 2018 in European Journal of Pharmacology
Verified
Journal Article
Closed access
PXPeng Xia
Peng Xia
HHHonglin He
Honglin He
MKModrak Samantha Kristine
Modrak Samantha Kristine
WGWen Guan
Wen Guan
JGJin Gao
Jin Gao
YYYan Yu
Yan Yu